Lifetime disease penetrance estimates for gastric cancer and breast cancer in patients bearing a P/LP variant in CDH1 are approximately 25–42% and 42–55%, respectively (Roberts et al., 2019; Xicola et al., 2019). This evidence concerns the gene CDH1 and gastric cancer.